Ceftriaxone in febrile neutropenia

Journal of Chemotherapy

Volumn 15, Issue 3, 2003, Pages 211-219

  Karthaus, Meinolf ^a,c   Cornely, O A ^b  

^a EVANGELISCHES KRANKENHAUS   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c NONE   (Germany)

Author keywords

Ceftriaxone; Febrile neutropenia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZLOCILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; FLUOROURACIL; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; SULTAMICILLIN; TEICOPLANIN; TOBRAMYCIN; UNINDEXED DRUG; UREIDOPENICILLIN;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; FEBRILE NEUTROPENIA; FEVER; HUMAN; INFECTIOUS COMPLICATION; MEDICAL LITERATURE; MORTALITY; PUBLICATION; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION;

EID: 0038345564     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.3.211     Document Type: Review

References (53)

1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
2. Karthaus M, Wolf HH, Kampfe D, et al. Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia. Chemotherapy 1998; 44: 343-354.
3. Link H, Maschmeyer G, Meyer P, et al. Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy. Ann Hematol 1994; 69: 231-243.
4. Bodey GP: Infection in cancer patients. A continuing association. Am J Med 1986; 81: 11-26.
5. Maschmeyer G, Hiddemann W, Link H, et al. Management of infections during intensive treatment of hematologic malignancies. Ann Hematol 1997; 75: 9-16.
6. Frei E 3d, Levin RH, Bodey GP, Morse EE, Freireich EJ. The nature and control of infections in patients with acute leukemia. Cancer Res 1965; 25: 1511-1515.
7. Klastersky J, Zinner SH, Calandra T, et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 1988; 24 Suppl 1: S35-S45.
8. Rolston KV, Raad I, Whimbey E, et al. The changing spectrum of bacterial infections in febrile neutropenic patients; in Klastersky J (ed): Febrile Neutropenia. Berlin, Springer, 1997: 53-56.
9. Bodey GP. Pseudomonas aeruginosa infections in cancer patients: have they gone away? Curr Opin Infect Dis 2001; 14: 403-407.
10. Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-259.
11. Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med 1977; 62: 731-742.
12. Furno P, Dionisi MS, Bucaneve G, Menichetti F, Del Favero A. Ceftriaxone versus beta-lactams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: a meta-analysis. Support Care Cancer 2000 Jul 2001; 8: 293-301.
13. Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051.
14. Finberg RW, Talcott JA. Fever and neutropenia - How to use a new treatment strategy. N Engl J Med 1999; 341: 362-363.
15. Karthaus M, Ganser A, Boehme A, et al. Important aspects of cost-effectiveness analysis in febrile neutropenia. Infection 1999; 27: 372-375.
16. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148: 2561-2568.
17. Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10: 316-322.
18. Blanc C, Pollet JP, Bauters F. Ceftriaxone plus amikacin in neutropenic patients: a report on 100 cases. Chemotherapy 1991; 37: 382-388.
19. Calandra T, Zinner S, Viscoli C, et al. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-593.
20. Fauser AA, Lang E, Kochling G, et al. A randomized clinical trial of ceftriaxone and teicoplanin versus ceftazidime and teicoplanin as antibiotic therapy in febrile neutropenic cancer patients and bone marrow transplant recipients. Infection 1994; 22: 271-275.
21. Schaison GS, Decroly FC. Prophylaxis, cost and effectiveness of therapy of infections caused by gram-positive organisms in neutropenic children. J Antimicrob Chemother 1991; 27 Suppl B: 61-67.
22. Smith L, Will AM, Williams RF, et al. Ceftriaxone vs.azlocillin and netilmicin in the treatment of febrile neutropenic children. J Infect 1990; 20: 201-206.
23. EORTC-International Antimicrobial Therapy Cooperative Group: Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-593.
24. Charnas R, Luthi AR, Ruch W. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. Pediatr Infect Dis J 1997; 16: 346-353.
25. Pession A, Prete A, Paolucci G. Cost-Effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer. Chemotherapy 1997; 43: 358-366.
26. Castagnola E, Lanino E, Giacchino R, et al. Strategies for cost-containment: once-daily ceftriaxone plus amikacin as empiric therapy for febrile granulocytopenic children with cancer. J Chemother 1999; 11: 54-60.
27. Menichetti F, Del Favero A, Bucaneve G, et al. Ceftriaxone versus aztreonam plus cefazolin for infections in cancer patients with adequate neutrophil counts. Infection 1990; 18: 166-169.
28. Cornely OA, Bethe U, Seifert H, et al. A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin. Ann Hematol 2002; 81: 37-43.
29. Martino P, Girmenia C, Raccah R, et al. Singel daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematological malignancies. Clin Infect Dis 1999; 29: 515-521.
30. Minotti V, Gentile G, Bucaneve G, et al. Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer 1999; 7: 134-9.
31. Paganini HR, Sarkis CM, De Martino MG, et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer 2001; 88: 2848-2852.
32. Karthaus M, Egerer G, Kullmann KH, et al. Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Eur J Clin Microbiol Infect Dis 1998; 17: 501-504.
33. Mustafa MM, Aquino VM, Pappo A, et al. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 1996; 128: 847-849.
34. Preis S, Jurgens H, Friedland C, Oudekotte-David AA, Thomas L, Gobel U. Ceftriaxone alone or in combination with teicoplanin in the management of febrile episodes in neutropenic children and adolescents with cancer on an outpatient base. Klin Padiatr 1993; 205: 295-299.
35. Sahu S, Bapna A, Pai SK, et al. Outpatient antimicrobial protocol for febrile neutropenia: a nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents. Pediatr Hematol Oncol 1997; 14: 205-211.
36. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71: 3640-3646.
37. Rubenstein EB, Rolston K. Outpatient management of febrile episodes in neutropenic cancer patients. Support Care Cancer 1994; 2: 369-373.
38. Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 1999; 85: 213-219.
39. Anaissie EJ, Samonis G, Kalbakis K, et al. Therapy for low-risk cancer patients with fever and neutropenia: results of a prospective randomized trial with cost analysis. Proceedings 37th ICAAC 1997; Toronto: 373-LM-51.
40. Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol 2000; 34: 87-91.
41. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233-239.
42. Polk R, Johnson C, Clarke J, et al. Virginia Commonwealth University, Richmond, Va; Trends in Fluoroquinolone (FQ) Prescribing in 35 U.S. Hospitals and Resistance for P. aeruginosa: A SCOPE-MMIT Report. MultiMedia Information Technologies Abstract. DATE?
43. Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999. MMWR Morbid Mortal Wkly Rep 2001; 50: 800-804.
44. Graham KK, Hufcut RM, Copeland CM, et al. Fluoroquinolone exposure and the development of nosocomial MRSA bacteremia. Infect Cont Hosp Epidemiol 2000; 21: 90.
45. Karlowsky JA, Jones ME, Mayfield DC, et al. Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from the Surveillance Network Database-USA. Int J Antimicrob Agents 2002; 19: 413-426
46. Rolston KV, Jones PG, Fainstein V, et al. Single agent therapy for infections in cancer patients: a prospective randomized trial comparing three extended-spectrum cephalosporins. Eur J Clin Microbiol Infect Dis 1991; 10: 139-145.
47. Petrilli AS, Melaragno R, Barros KV, et al. Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease [see comments]. Pediatr Infect Dis J 1993; 12: 916-921.
48. Cornely OA, Salzberger B, Bethe U, et al. Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever. Ann Hematol 2001; 80: 103-108.
49. Leoni F, Ciolli S, Pascarella A, et al. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients. Chemotherapy 1993; 39: 147-152.
50. Gibson J, Johnson I, Snowdon L, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomized trial. Int J Hematol 1993; 58: 63-72.
51. Bucaneve G, Menichetti F, Minotti V, Pasticci MB, Tonato M, Del Favero A. Ceftriaxone versus imipenem/cilastin as empirical monotherapy for infections in cancer patients. Chemotherapy 1989; 35 Suppl. 2: 10-15.
52. Girmenia C, Moleti ML, Cartoni C, et al. Management of infective complications in patients with advanced hematologic malignancies in home care. Leukemia 1997; 11: 1807-12.
53. Kaplinsky C, Drucker M, Goshen J, et al. Ambulatory treatment with ceftriaxone in febrile neutropenic children. Isr J Med Sci 1994; 30: 649-651.